Phase 1 Study of No-Carrier Added (177)Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea

PURPOSE: To provide a wider choice of treatment opportunities for patients with neuroendocrine tumor (NET) in Korea, we have conducted a phase 1, open-label, single-arm, dose-escalation study of SNU-KB-01, a no-carrier added (NCA) (177)Lu-labeled DOTATATE. MATERIALS AND METHODS: Seven patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryoo, Hyun Gee, Suh, Minseok, Kang, Keon Wook, Lee, Dae-Won, Han, Sae-Won, Cheon, Gi Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873339/
https://www.ncbi.nlm.nih.gov/pubmed/35468268
http://dx.doi.org/10.4143/crt.2021.1022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873339/
https://www.ncbi.nlm.nih.gov/pubmed/35468268
http://dx.doi.org/10.4143/crt.2021.1022

Ejemplares similares